Evolus Lifts 2026 Guidance After Third Consecutive Quarter of Positive Adjusted EBITDA
Market Chameleon (Thu, 6-Aug 7:16 AM ET)
Business Wire (Wed, 5-Aug 4:05 PM ET)
Business Wire (Tue, 4-Aug 8:30 AM ET)
Evolus to Report Second Quarter Financial Results on August 5, 2026
Business Wire (Wed, 22-Jul 8:30 AM ET)
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Business Wire (Fri, 10-Jul 4:05 PM ET)
PRNewswire (Thu, 9-Jul 8:17 AM ET)
Business Wire (Wed, 8-Jul 9:00 AM ET)
Evolus to Participate in The Jefferies Global Healthcare Conference
Business Wire (Tue, 19-May 8:30 AM ET)
Evolus Sets Sights on Profitability in 2026, Forecasts Strong Double-Digit Revenue Growth
Market Chameleon (Fri, 9-Jan 3:57 AM ET)
Evolus Outpaces Market Trends with Record Jeuveau® Sales and Strong Evolysse™ Launch in Q3 2025
Market Chameleon (Thu, 6-Nov 6:22 AM ET)
Evolus Inc is a performance beauty company offering medical aesthetic products in the cash-pay aesthetic market. The company's commercially available products represent two product categories within medical aesthetics: injectable neurotoxins and injectable hyaluronic acid (HA) gels. Its commercial products are: Jeuveau, a proprietary 900-kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe frown lines, in adults; and Evolysse, a collection of injectable HA gels that utilizes first-generation cold technology. The line includes several products, including mid face, nasolabial folds, lips, and eyes. Geographically, the company currently has operations in the United States, Canada, Europe, and Australia.
Evolus trades on the NASDAQ stock market under the symbol EOLS.
As of August 14, 2026, EOLS stock price climbed to $8.15 with 604,118 million shares trading.
EOLS has a beta of 0.83, meaning it tends to be less sensitive to market movements. EOLS has a correlation of 0.02 to the broad based SPY ETF.
EOLS has a market cap of $538.64 million. This is considered a Small Cap stock.
Last quarter Evolus reported $84 million in Revenue and -$.12 earnings per share. This beat revenue expectation by $2 million and missed earnings estimates by -$.07.
In the last 3 years, EOLS traded as high as $17.82 and as low as $3.86.
The top ETF exchange traded funds that EOLS belongs to (by Net Assets): IWM, VTI, VXF, IWO, XPH.
EOLS has outperformed the market in the last year with a price return of +25.3% while the SPY ETF gained +21.6%. EOLS has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +21.4% and +35.7%, respectively, while the SPY returned +4.8% and +4.7%, respectively.
EOLS support price is $7.69 and resistance is $8.35 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that EOLS shares will trade within this expected range on the day.
